CYP19A1
Aromatase
As of the edition of 20 October 2026, CYP19A1 (aromatase, UniProt P11511) has 8 drugs tested at it and 8 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11511
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 11
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Hormones; Nutrition and metabolism; Bones, joints and muscles; Inherited and neonatal
- Registered trials of its drugs
- 840
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Letrozole | Marketed | Phase 4 | Ends 2031 |
| Anastrozole | Marketed | Phase 4 | none listed |
| Exemestane | Marketed | Phase 4 | none listed |
| Atamestane | Stopped | Phase 3 | none listed |
| Testolactone | Marketed | Phase 4 | none listed |
| Aminoglutethimide | Marketed | Phase 3 | none listed |
| D309 | Status not established | Phase 1 | none listed |
| Dexfadrostat | Status not established | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| AstraZeneca | Route B |
| Novartis | Route B |
The other 5 companies at CYP19A1
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at CYP19A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.